Navigation Links
Asenapine Meets Primary Endpoint in Long-Term Schizophrenia Relapse Prevention Trial
Date:10/23/2008

KENILWORTH, N.J., Oct. 23 /PRNewswire-FirstCall/ -- Schering-Plough Corporation (NYSE: SGP) today announced that its novel psychopharmacologic agent asenapine has met the primary endpoint in a long-term schizophrenia relapse prevention trial. Asenapine, which is administered as a fast-dissolving sublingual tablet, is a psychopharmacologic compound with a unique human receptor signature.

The study was a randomized, placebo-controlled, double-blind, multicenter, multinational clinical trial evaluating the efficacy and safety of sublingually administered asenapine (5 or 10 mg BID) compared to placebo in the prevention of relapse in subjects with schizophrenia. A total of 700 subjects entered the open-label treatment with asenapine for up to 26 weeks. Of these, a total of 386 subjects met criteria for stabilization on asenapine and were randomized to treatment in the 26-week double-blind placebo-controlled phase of the trial.

Asenapine was statistically significantly more effective than placebo in preventing relapse, the primary endpoint of the trial. Asenapine was generally well tolerated during the trial. Full results of the trial, including efficacy, safety and tolerability data will be presented at a later date. These data are planned to be used to support a regulatory submission for the approval of asenapine in Europe.

Schering-Plough acquired asenapine in November 2007 through its acquisition of Organon BioSciences, which developed the product. Asenapine is currently under review by the U.S. Food and Drug Administration for the treatment of schizophrenia and acute manic or mixed episodes associated with bipolar I disorder.

Schering-Plough is an innovation-driven, science-centered global health care company. Th
'/>"/>

SOURCE Schering-Plough
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Organons Asenapine Further Demonstrates Efficacy in Reducing Mania Symptoms for the Treatment of Bipolar I Disorder
2. World Think Tank on Type 1 Diabetes Meets in Miami
3. Genzyme Study of Myozyme(R) for Late-Onset Pompe Patients Meets Co-Primary Efficacy Endpoints
4. Axial Biotech Meets Major Scientific Milestones; Receives $6 Million Tranche of Series B Financing
5. Vermillion Meets Minimum Bid Price and Receives NASDAQ Staff Determination Letter for Minimum Market Capitalization
6. Atherotech VAP Cholesterol Test Meets Updated ADA, ACC Measurement and Treatment Guidelines for High Risk Patients
7. The Science of Music Meets the Art of Medicine - ARIMM 3rd Annual Conference at IPFW, September 12-13, 2008
8. Teliks Aurora Kinase-VEGFR Dual Inhibitor Program Meets a Preclinical Development Milestone
9. Cequent Pharmaceuticals Meets Novartis Option Fund Milestone; Continues to Next Phase to Validate Inflammatory Bowel Disease Targets in Vivo
10. OncoGenex reports lead drug candidate OGX-011 achieved primary endpoint in Phase 2 Trial with second-line chemotherapy for prostate cancer
11. Keryx Biopharmaceuticals Announces that SUN-MICRO Phase 3 Clinical Trial Fails to Meet Primary Efficacy Endpoint
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2015)... May 5, 2015  Indianapolis-based medical device manufacturer ... innovative line of products including the BrainPath® and ... accessing deep-seated brain abnormalities and then removing affected ... at more than 50 institutions throughout ... also been included in 12 abstracts, three peer-reviewed ...
(Date:5/5/2015)... May 05, 2015 The Alliance for ... Massachusetts-based non-profit operating in the public interest, and Texas-based ... the Hearst Communications Company, have formed a strategic alliance ... outreach and education across the healthcare and clinical research ... voice of patients and the public to be clearly ...
(Date:5/4/2015)... May 4, 2015 Tobira Therapeutics, Inc. ... the development and commercialization of novel treatments for ... of its merger with Regado Biosciences, Inc. (NASDAQ: ... closing of the merger, Tobira raised $40 million ... investors and all current Tobira institutional investors, including ...
(Date:5/4/2015)... 4, 2015   St. Jude Children,s Research ... computer tool for finding genetic alterations that play ... difficult to identify with whole-genome sequencing. The findings ... Methods . The tool is an ... by Regression Tree in Next Generation Sequencing. ...
Breaking Biology Technology:NICO Corporation Gains Market Expansion after Multiple Published Clinical Articles Support Access Technology for Deep Brain Lesions 2NICO Corporation Gains Market Expansion after Multiple Published Clinical Articles Support Access Technology for Deep Brain Lesions 3ACRES and San Antonio Express-News Launch Blog on Accountability in Clinical Research 2ACRES and San Antonio Express-News Launch Blog on Accountability in Clinical Research 3ACRES and San Antonio Express-News Launch Blog on Accountability in Clinical Research 4Tobira Therapeutics Completes Financing and Merger with Regado Biosciences 2Tobira Therapeutics Completes Financing and Merger with Regado Biosciences 3Tobira Therapeutics Completes Financing and Merger with Regado Biosciences 4Tobira Therapeutics Completes Financing and Merger with Regado Biosciences 5Tobira Therapeutics Completes Financing and Merger with Regado Biosciences 6Scientists dramatically improve method for finding common genetic alterations in tumors 2Scientists dramatically improve method for finding common genetic alterations in tumors 3Scientists dramatically improve method for finding common genetic alterations in tumors 4
... will be presented during the American Transplant Congress in ... Md., May 30 Lead investigator, Dr. Manuel R. ... of Miami , evaluated whether single or serial ImmuKnow ... in kidney transplant recipients. Patients were randomly selected after ...
... (Nasdaq: ONTY ) (TSX:ONY) (the "Company") today ... the Company,s product candidates were presented at the American ... 30, 2009 in Orlando, Florida. The presentations included long-term ... in patients with stage IIIB/IV non-small cell lung cancer, ...
... 29 TorreyPines Therapeutics, Inc. (Nasdaq: TPTX ... determined, after consideration of potential strategic and financing alternatives, ... Company and its stockholders to liquidate the Company,s assets ... Directors has unanimously approved a Plan of Liquidation and ...
Cached Biology Technology:Serial Monitoring With ImmuKnow(R) is Useful in the Risk Assessment of Kidney Transplant Recipients 2Oncothyreon announces clinical data from three product candidates presented at American Society of Clinical Oncology (ASCO) Annual Meeting 2Oncothyreon announces clinical data from three product candidates presented at American Society of Clinical Oncology (ASCO) Annual Meeting 3Oncothyreon announces clinical data from three product candidates presented at American Society of Clinical Oncology (ASCO) Annual Meeting 4Oncothyreon announces clinical data from three product candidates presented at American Society of Clinical Oncology (ASCO) Annual Meeting 5Oncothyreon announces clinical data from three product candidates presented at American Society of Clinical Oncology (ASCO) Annual Meeting 6TorreyPines Therapeutics Announces its Board of Directors' Approval of Plan of Liquidation and Dissolution 2TorreyPines Therapeutics Announces its Board of Directors' Approval of Plan of Liquidation and Dissolution 3
(Date:4/6/2015)... Conn. , Apr. 6, 2015 NXT-ID, ... "Company"), a biometric authentication company focused on the ... has filed provisional patent 62/143028 for ... COMMUNICATIONS AND ENERGY TRANSFER  NXT-ID introduces a ... payments. This patent surrounds the use of miniature ...
(Date:4/2/2015)... -- Fingerprint Cards (FPC) has received an ... distributor World Peace Industrial Group (WPI), part of WPG ... major part of the shipments will take place during ... manufacturers in China . The order ... revenue guidance of + 1 000 MSEK for 2015.  ...
(Date:3/31/2015)... 2015   Guidepoint , a leading global research ... Pain Management TRACKER, part of the Guidepoint TRACKER ... the medical device and therapeutics markets. The Post-Surgical Pain ... volumes, market share, and adoption rates across three major ... surgery. The Post-Surgical Pain Management TRACKER will ...
Breaking Biology News(10 mins):NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 2NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 3NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 4Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 110 Million 2Guidepoint Launches Post-Surgical Pain Management TRACKER 2Guidepoint Launches Post-Surgical Pain Management TRACKER 3
... The San Francisco State University Department of Biology has ... Medical Institute (HHMI) to support the faculty as they ... new ways to assess their students, learning. The ... will support a new program called Biology Faculty Explorations ...
... of British Columbia and the Smithsonian Institution have discovered a ... behaviour and may help explain their enormous size. ... blue, fin, minke and humpback whales. They are characterized by ... to the navel. The blubber expands up to several times ...
... by researchers from Boston University School of Medicine (BUSM) ... preferences for social, spiritual and political behaviors. The findings, ... Genetic Syndromes and Gene Therapy , also suggests ... more than the actual issues at hand or the ...
Cached Biology News:SF State biology department receives $1.5 million to support science teaching 2A whale of a discovery: New sensory organ found in rorqual whales 2Study finds voter genetics may predict election outcomes 2
Sheep polyclonal to Quinolone ( Abpromise for all tested applications). Antigen: Norfloxacin(N)conjugated to BSA...
DONOR BOVINE SERUM AND PLASMA...
The Magnetic Separation Rack is designed to be used for small-scale separations using magnetic particles. ,Capacity: 6 microcentrifuge tubes....
5(S)-HETE-d8 is used as an internal standard for the quantification of 5(S)-HETE by stable isotope dilution mass spectrometry....
Biology Products: